Clinical Trials Browser

Phase 2 × daratumumab × 30 days × Clear all

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT04133636 2026-03-17

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT06353022 2026-03-17

IFm2022-01

Phase 2 Active not recruiting

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05896228 2026-03-11

Iber-KDd

Phase 2 Recruiting

Multiple Myeloma

NCT05807048 2026-03-10

Daratumumab in STK11 Mutated NSCLC

Phase 2 Completed

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

NCT03477539 2026-03-09

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Phase 2 Completed

49 enrolled 15 charts

Multiple Myeloma

NCT06083922 2026-03-06

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2 Recruiting

Multiple Myeloma

NCT04656951 2026-03-05

GMMG-DADA

Phase 2 Active not recruiting

Multiple Myeloma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05289687 2026-03-02

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT04933539 2026-02-27

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma